Invited Lecture

Neurological Sciences

, Volume 32, Supplement 1, pp 105-109

First online:

New frontiers in headache therapy

  • A. RapoportAffiliated withDavid Geffen School of Medicine at UCLADirector Emeritus of The New England Center for Headache Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

There are numerous headache therapies available for our patients, more for migraine than for any of the other primary headache disorders. Only four medications have been approved for migraine prevention in the last few decades in the US and onabotulinumtoxinA was recently approved in the UK and the US for chronic migraine. We have been more fortunate in the acute care arena where in the US we have had seven triptans and one nonsteroidal anti-inflammatory medication approved by the FDA and currently available. There are several other acute care medications in various stages of development and there are two new methods of administering a triptan and others under investigation. We are always looking for faster, easier and more efficient administration of medications with fewer adverse events, as optimal migraine therapy requires these characteristics. What follows is a brief review of the progress in development for four of the many new acute care medications being investigated: the CGRP antagonist tablet telcagepant, the sumatriptan iontophoretic patch, sumatriptan powder for use in the OptiNose apparatus and the dihydroergotamine oral inhaler. I will not include transcranial magnetic stimulation, a 5-HT1F agonist, large conductance calcium-activated potassium channel openers, glial modulators or other medications and devices in early stages of development [1].

Keywords

Migraine treatment Migraine pipeline CGRP antagonists Sumatriptan Dihydroergotamine